Christmas has come early this year for Santaris Pharma A/S. Just one day after closing a new financing round of €20.4 million (US$29.4 million), the Copenhagen, Denmark-based company unveiled a broadly based drug discovery and development alliance with GlaxoSmithKline plc that could be worth more than $700 million in up-front, milestone and equity payments. (BioWorld International)
RSS